Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 105 articles:
HTML format
Text format



Single Articles


    April 2017
  1. WEERTS MJA, Hollestelle A, Sieuwerts AM, Foekens JA, et al
    Low Tumor Mitochondrial DNA Content is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-based Chemotherapy.
    Clin Cancer Res. 2017 Apr 18. pii: clincanres.0032.2017.
    PubMed     Text format     Abstract available


  2. ASSADIPOUR Y, Zacharakis N, Crystal JS, Prickett TD, et al
    Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2017 Apr 4. pii: clincanres.1423.2016.
    PubMed     Text format     Abstract available


    March 2017
  3. SOMLO G, Frankel P, Arun B, Ma CX, et al
    Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 29. pii: clincanres.2714.2016.
    PubMed     Text format     Abstract available


  4. PITRODA S, Bao R, Andrade J, Weichselbaum RR, et al
    Low Recombination Proficiency Score (RPS) predicts heightened sensitivity to DNA-damaging chemotherapy in breast cancer.
    Clin Cancer Res. 2017 Mar 24. pii: clincanres.2845.2016.
    PubMed     Text format     Abstract available


  5. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Text format     Abstract available


  6. SCHWARTZBERG LS, Yardley D, Elias A, Patel M, et al
    A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2339.2016.
    PubMed     Text format     Abstract available


  7. JOVANOVIC B, Mayer IA, Mayer EL, Abramson VG, et al
    A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC).
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3055.2016.
    PubMed     Text format     Abstract available


  8. MA CX, Gao F, Luo J, Northfelt DW, et al
    NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer.
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3206.2016.
    PubMed     Text format     Abstract available


    February 2017
  9. HUSING A, Fortner RT, Kuhn T, Overvad K, et al
    Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: Results from the EPIC cohort.
    Clin Cancer Res. 2017 Feb 28. pii: clincanres.3011.2016.
    PubMed     Text format     Abstract available


    January 2017
  10. SHACHAR SS, Deal AM, Weinberg M, Williams GR, et al
    Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane Based Chemotherapy for Early Stage Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2266.2016.
    PubMed     Text format     Abstract available


  11. SINGER CF, Tan YY, Fitzal F, Steger GG, et al
    Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2373.2016.
    PubMed     Text format     Abstract available


  12. DEGNIM AC, Hoskin TL, Arshad M, Frost MH, et al
    Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.
    Clin Cancer Res. 2017 Jan 26. pii: clincanres.2026.2016.
    PubMed     Text format     Abstract available



  13. Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90.
    Clin Cancer Res. 2017;23:612.
    PubMed     Text format    


  14. AFGHAHI A, Timms KM, Vinayak S, Jensen KC, et al
    Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.2174.2016.
    PubMed     Text format     Abstract available


  15. HART CD, Vignoli A, Tenori L, Uy GL, et al
    Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
    Clin Cancer Res. 2017 Jan 12. doi: 10.1158/1078-0432.CCR-16-1153.
    PubMed     Text format     Abstract available


  16. WU J, Cui Y, Sun X, Cao G, et al
    Unsupervised clustering of quantitative image phenotypes reveals breast cancer subtypes with distinct prognoses and molecular pathways.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2415.2016.
    PubMed     Text format     Abstract available


  17. CARDILLO TM, Sharkey RM, Rossi DL, Arrojo R, et al
    Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP-inhibitors in BRCA1/2-wild-type triple-negative breast cancer.
    Clin Cancer Res. 2017 Jan 9. pii: clincanres.2401.2016.
    PubMed     Text format     Abstract available


  18. MOULDER-THOMPSON S, Borges VF, Baetz TD, Mcspadden T, et al
    Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).
    Clin Cancer Res. 2017 Jan 4. pii: clincanres.1496.2016.
    PubMed     Text format     Abstract available


    December 2016
  19. LIU Y, Burness ML, Martin-Trevino R, Guy J, et al
    RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2016 Dec 29. doi: 10.1158/1078-0432.CCR-15-1348.
    PubMed     Text format     Abstract available


  20. HUMPHRIES MP, Sundara Rajan S, Droop A, Suleman C, et al
    A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.1952.2016.
    PubMed     Text format     Abstract available


  21. CONNOLLY R, Li H, Jankowitz RC, Zhang Z, et al
    Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1729.2016.
    PubMed     Text format     Abstract available


  22. JANKOWITZ RC, Oesterreich S, Lee AV, Davidson NE, et al
    New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and other Targeted Therapies.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.0591.2016.
    PubMed     Text format     Abstract available


  23. LECONET W, Chentouf M, Du Manoir S, Chevalier C, et al
    Therapeutic activity of anti-AXL antibody against triple-negative breast cancer Patient Derived Xenografts and metastasis.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.1316.2016.
    PubMed     Text format     Abstract available


    November 2016
  24. HOSFORD SR, Dillon LM, Bouley SJ, Rosati R, et al
    Combined inhibition of both p110alpha and p110beta isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER+ breast cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.2764.2015.
    PubMed     Text format     Abstract available


  25. PRAT A, Lluch A, Turnbull AK, Dunbier AK, et al
    A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.2092.2016.
    PubMed     Text format     Abstract available


  26. HUNT KK, Karakas C, Ha MJ, Biernacka A, et al
    Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
    Clin Cancer Res. 2016 Nov 23. pii: clincanres.2217.2016.
    PubMed     Text format     Abstract available


  27. LAMBERTS LE, Koch M, de Jong JS, Adams A, et al
    Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study.
    Clin Cancer Res. 2016 Nov 9. pii: clincanres.0437.2016.
    PubMed     Text format     Abstract available


  28. BOZOVIC-SPASOJEVIC I, Zardavas D, Brohee S, Ameye L, et al
    The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.
    Clin Cancer Res. 2016 Nov 9. pii: clincanres.0979.2016.
    PubMed     Text format     Abstract available


  29. ELEBRO K, Borgquist S, Rosendahl AH, Markkula A, et al
    High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients - results from a population-based breast cancer cohort.
    Clin Cancer Res. 2016 Nov 3. pii: clincanres.1095.2016.
    PubMed     Text format     Abstract available


  30. BRAND JS, Hedayati E, Humphreys K, Ludvigsson JF, et al
    Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.
    Clin Cancer Res. 2016;22:5249-5255.
    PubMed     Text format     Abstract available


    October 2016
  31. CHAN N, Willis A, Kornhauser N, Ward MM, et al
    Influencing the tumor microenvironment: Phase 2 Study of Copper depletion with tetrathiomolybdate in high risk breast cancer and preclinical models of lung metastases.
    Clin Cancer Res. 2016 Oct 21. pii: clincanres.1326.2016.
    PubMed     Text format     Abstract available


  32. ZEMBUTSU H, Nakamura S, Akashi ST, Kuwayama T, et al
    Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer; a Prospective Multicenter Study.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1779.2016.
    PubMed     Text format     Abstract available


  33. BRECHBUHL HM, Finlay-Schultz J, Yamamoto T, Gillen A, et al
    Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.2851.2015.
    PubMed     Text format     Abstract available


  34. MERCOGLIANO MF, De Martino M, Venturutti L, Rivas MA, et al
    TNFalpha-induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.0970.2016.
    PubMed     Text format     Abstract available


  35. ZUO WJ, Jiang YZ, Wang YJ, Xu XE, et al
    Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.
    Clin Cancer Res. 2016;22:4859-4869.
    PubMed     Text format     Abstract available


    September 2016
  36. RENNERT G, Pinchev M, Gronich N, Saliba W, et al
    Oral bisphosphonates and improved survival of breast cancer.
    Clin Cancer Res. 2016 Sep 28. pii: clincanres.0547.2016.
    PubMed     Text format     Abstract available



  37. Correction: Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C Alpha.
    Clin Cancer Res. 2016;22:4756.
    PubMed     Text format    


  38. LIPS EH, Debipersad R, Scheerman CE, Mulder L, et al
    BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0198.2016.
    PubMed     Text format     Abstract available


  39. NIELSEN TO, Jensen MB, Burugu S, Gao D, et al
    High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1278.2016.
    PubMed     Text format     Abstract available


  40. VON WAHLDE MK, Timms KM, Chagpar AB, Wali VB, et al
    Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.0889.2016.
    PubMed     Text format     Abstract available



  41. Correction: Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
    Clin Cancer Res. 2016;22:4536.
    PubMed     Text format    


  42. QUINTELA-FANDINO M, Lluch A, Manso LM, Calvo I, et al
    18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial.
    Clin Cancer Res. 2016 Sep 1. pii: clincanres.0738.2016.
    PubMed     Text format     Abstract available


    August 2016
  43. MCARTHUR HL, Diab A, Page DB, Yuan J, et al
    A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling.
    Clin Cancer Res. 2016 Aug 26. pii: clincanres.0190.2016.
    PubMed     Text format     Abstract available


  44. BRUFSKY AM, Davidson NE
    Multi-parametric genomic assays for breast cancer: Time for the next generation?
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1513.2016.
    PubMed     Text format     Abstract available


  45. PARSONS HA, Beaver JA, Cimino-Mathews A, Ali SM, et al
    Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.1543.2016.
    PubMed     Text format     Abstract available


  46. STRULOV SHACHAR S, Deal AM, Weinberg M, Nyrop KA, et al
    Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane Based Chemotherapy.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.0940.2016.
    PubMed     Text format     Abstract available


    July 2016
  47. SAMAEEKIA R, Adorno-Cruz V, Bockhorn J, Chang YF, et al
    MicroRNA-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0943.2016.
    PubMed     Text format     Abstract available


  48. AL-AZHRI J, Zhang Y, Bshara W, Zirpoli GR, et al
    Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0075.2016.
    PubMed     Text format     Abstract available


  49. WALKER AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, et al
    FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0493.2016.
    PubMed     Text format     Abstract available


    June 2016
  50. KURLAND BF, Peterson LM, Lee JH, Schubert EK, et al
    Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
    Clin Cancer Res. 2016 Jun 24. pii: clincanres.0362.2016.
    PubMed     Text format     Abstract available


  51. SHAW JA, Guttery DS, Hills A, Fernandez-Garcia D, et al
    Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts.
    Clin Cancer Res. 2016 Jun 22. pii: clincanres.0825.2016.
    PubMed     Text format     Abstract available


  52. STOVER DG, Coloff JL, Barry WT, Brugge JS, et al
    The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
    Clin Cancer Res. 2016 Jun 21. pii: clincanres.0471.2016.
    PubMed     Text format     Abstract available


  53. PATEL H, Abduljabbar R, Lai CF, Periyasamy M, et al
    CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer.
    Clin Cancer Res. 2016 Jun 14. pii: clincanres.1104.2015.
    PubMed     Text format     Abstract available


  54. SHARMA P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, et al
    Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts.
    Clin Cancer Res. 2016 Jun 14. pii: clincanres.0162.2016.
    PubMed     Text format     Abstract available


  55. LI W, O'Shaughnessy JA, Hayes DF, Campone M, et al
    Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2452.2015.
    PubMed     Text format     Abstract available


  56. WANG ZQ, Milne K, Derocher H, Webb JR, et al
    CD103 and Intratumoral Immune Response in Breast Cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.0732.2016.
    PubMed     Text format     Abstract available


  57. ALVES CL, Elias D, Lyng MB, Bak M, et al
    High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.1984.2015.
    PubMed     Text format     Abstract available


  58. SESTAK I, Zhang Y, Schroeder BE, Schnabel CA, et al
    Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.0155.2016.
    PubMed     Text format     Abstract available



  59. Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer.
    Clin Cancer Res. 2016;22:2825.
    PubMed     Text format    


    May 2016
  60. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
    Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
    Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
    PubMed     Text format     Abstract available


  61. SPEERS C, Zhao SG, Kothari V, Santola A, et al
    Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer.
    Clin Cancer Res. 2016 May 25. pii: clincanres.2711.2015.
    PubMed     Text format     Abstract available


  62. INGOLD HEPPNER B, Untch M, Denkert C, Pfitzner BM, et al
    Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2-positive breast cancer.
    Clin Cancer Res. 2016 May 17. pii: clincanres.2338.2015.
    PubMed     Text format     Abstract available


  63. JESELSOHN R, Barry WT, Migliaccio I, Biagioni C, et al
    TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer.
    Clin Cancer Res. 2016 May 16. pii: clincanres.0148.2016.
    PubMed     Text format     Abstract available


  64. GYANCHANDANI R, Lin Y, Lin HM, Cooper KL, et al
    Intra-tumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer.
    Clin Cancer Res. 2016 May 16. pii: clincanres.2889.2015.
    PubMed     Text format     Abstract available


  65. KLINTMAN M, Buus R, Cheang MC, Sheri A, et al
    Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
    Clin Cancer Res. 2016;22:2405-16.
    PubMed     Text format     Abstract available


  66. DENNISON JB, Shahmoradgoli M, Liu W, Ju Z, et al
    High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype.
    Clin Cancer Res. 2016 May 12. pii: clincanres.0171.2016.
    PubMed     Text format     Abstract available


  67. MITRI Z, Nanda R, Blackwell K, Costelloe CM, et al
    TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
    Clin Cancer Res. 2016 May 10. pii: clincanres.2845.2015.
    PubMed     Text format     Abstract available


  68. GILANI R, Phadke S, Bao LW, Lachacz E, et al
    UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer.
    Clin Cancer Res. 2016 May 6. pii: clincanres.2158.2015.
    PubMed     Text format     Abstract available


  69. CLAVAREZZA M, Puntoni M, Gennari A, Paleari L, et al
    Dual block with lapatinib and trastuzumab versus single agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials.
    Clin Cancer Res. 2016 May 2. pii: clincanres.1881.2015.
    PubMed     Text format     Abstract available


    April 2016
  70. MAYER IA, Abramson V, Formisano L, Balko JM, et al
    A Phase Ib Study of Alpelisib (BYL719), a PI3Kalpha-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Apr 28. pii: clincanres.0134.2016.
    PubMed     Text format     Abstract available


  71. GIRO-PERAFITA A, Palomeras S, Lum D, Blancafort A, et al
    Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple Negative Breast Cancer.
    Clin Cancer Res. 2016 Apr 22. pii: clincanres.3133.2016.
    PubMed     Text format     Abstract available


  72. DALIN MG, Desrichard A, Katabi N, Makarov V, et al
    Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer.
    Clin Cancer Res. 2016 Apr 21. pii: clincanres.0637.2016.
    PubMed     Text format     Abstract available


  73. HUNG AC, Lo S, Hou MF, Lee YC, et al
    Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
    Clin Cancer Res. 2016 Apr 1. pii: clincanres.2704.2015.
    PubMed     Text format     Abstract available


    March 2016
  74. WISINSKI KB, Tevaarwerk AJ, Burkard ME, Rampurwalla M, et al
    Phase 1 study of an AKT-inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose-expansion in advanced HER2+ breast cancer.
    Clin Cancer Res. 2016 Mar 29. pii: clincanres.2365.2015.
    PubMed     Text format     Abstract available


  75. BASSIOUNI R, Nemec KN, Iketani A, Flores O, et al
    Chaperonin Containing-TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide.
    Clin Cancer Res. 2016 Mar 24. pii: clincanres.2502.2015.
    PubMed     Text format     Abstract available


  76. DADIANI M, Bossel Ben Moshe N, Shimon-Paluch S, Perry G, et al
    Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy and Recurrence in Breast Cancer.
    Clin Cancer Res. 2016 Mar 8. pii: clincanres.2313.2015.
    PubMed     Text format     Abstract available


  77. TELLI ML, Timms KM, Reid JE, Hennessy B, et al
    Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer.
    Clin Cancer Res. 2016 Mar 8. pii: clincanres.2477.2015.
    PubMed     Text format     Abstract available


    February 2016
  78. RAJAMANICKAM S, Panneerdoss S, Gorthi A, Timilsina S, et al
    Inhibition of FOXM1-Mediated DNA repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis.
    Clin Cancer Res. 2016 Feb 29. pii: clincanres.2535.2015.
    PubMed     Text format     Abstract available


  79. BASELGA J, Lewis Phillips GD, Verma S, Ro J, et al
    Relationship Between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Feb 26. pii: clincanres.2499.2015.
    PubMed     Text format     Abstract available


  80. KANNAN A, Wells RB, Shivkumar S, Komatsu S, et al
    Mitochondrial Reprogramming Regulates Breast Cancer Progression.
    Clin Cancer Res. 2016 Feb 17. pii: clincanres.2456.2015.
    PubMed     Text format     Abstract available


  81. PODO F, Santoro F, Di Leo G, Manoukian S, et al
    Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    Clin Cancer Res. 2016;22:895-904.
    PubMed     Text format     Abstract available


  82. SAMENI M, Tovar EA, Essenburg CJ, Chalasani A, et al
    Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Clin Cancer Res. 2016;22:923-34.
    PubMed     Text format     Abstract available


  83. CHU D, Paoletti C, Gersch C, VanDenBerg DA, et al
    ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
    Clin Cancer Res. 2016;22:993-9.
    PubMed     Text format     Abstract available


  84. ABDEL-FATAH TM, McArdle SE, Agarwal D, Moseley PM, et al
    HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Clin Cancer Res. 2016;22:905-14.
    PubMed     Text format     Abstract available


  85. PUSZTAI L, Karn T, Safonov A, Abu-Khalaf MM, et al
    New Strategies in Breast Cancer: Immunotherapy.
    Clin Cancer Res. 2016 Feb 11. pii: clincanres.1315.2015.
    PubMed     Text format     Abstract available


  86. VARADAN V, Gilmore HL, Miskimen KL, Tuck DP, et al
    Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.
    Clin Cancer Res. 2016 Feb 3. pii: clincanres.2021.2015.
    PubMed     Text format     Abstract available


    January 2016
  87. LAM SW, Nota NM, Jager A, Bos MM, et al
    Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  88. LIU YR, Jiang YZ, Xu XE, Hu X, et al
    Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  89. RODLER ET, Kurland BF, Griffin M, Gralow JR, et al
    Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
    Clin Cancer Res. 2016 Jan 22. pii: clincanres.2137.2015.
    PubMed     Text format     Abstract available


  90. MA CX, Sanchez C, Gao F, Crowder R, et al
    A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jan 18. pii: clincanres.2160.2015.
    PubMed     Text format     Abstract available


  91. VARESLIJA D, McBryan J, Fagan A, Redmond AM, et al
    Adaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen independent metastatic tumours.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.1583.2015.
    PubMed     Text format     Abstract available


  92. LOIBL S, Darb-Esfahani S, Huober J, Klimowicz A, et al
    PTEN EXPRESSION AND p4EBP1 IMMUNOREACTIVE SCORE AS PREDICTOR FOR pCR IN HER2 POSITIVE BREAST CANCER.
    Clin Cancer Res. 2016 Jan 12. pii: clincanres.0965.2015.
    PubMed     Text format     Abstract available


  93. JANNI W, Rack B, Terstappen LW, Pierga JY, et al
    Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.
    Clin Cancer Res. 2016 Jan 5. pii: clincanres.1603.2015.
    PubMed     Text format     Abstract available


  94. YANG W, Hosford SR, Dillon LM, Shee K, et al
    Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer.
    Clin Cancer Res. 2016 Jan 5. pii: clincanres.2276.2015.
    PubMed     Text format     Abstract available


  95. DEMICHELE A, Yee D, Paoloni M, Berry D, et al
    Neoadjuvant as Future for Drug Development in Breast Cancer-Response.
    Clin Cancer Res. 2016;22:269.
    PubMed     Text format    


  96. BUYSE M, Burzykowski T, Saad ED
    Neoadjuvant as Future for Drug Development in Breast Cancer-Letter.
    Clin Cancer Res. 2016;22:268.
    PubMed     Text format    


    December 2015
  97. IYENGAR NM, Zhou XK, Gucalp A, Morris PG, et al
    Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2239.2015.
    PubMed     Text format     Abstract available


  98. GU G, Fuqua SA
    ESR1 Mutations in Breast Cancer: Proof of Concept Challenges Clinical Action.
    Clin Cancer Res. 2015 Dec 23. pii: clincanres.2549.2015.
    PubMed     Text format     Abstract available


  99. BARONE I, Catalano S, Campana A, Giordano C, et al
    Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy.
    Clin Cancer Res. 2015 Dec 14. pii: clincanres.1900.2015.
    PubMed     Text format     Abstract available


    November 2015
  100. MOON PG, Lee JE, Cho YE, Lee SJ, et al
    Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection.
    Clin Cancer Res. 2015 Nov 24. pii: clincanres.0654.2015.
    PubMed     Text format     Abstract available


  101. MA CX, Luo J, Naughton M, Ademuyiwa FO, et al
    A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
    Clin Cancer Res. 2015 Nov 12. pii: clincanres.1745.2015.
    PubMed     Text format     Abstract available


  102. MO W, Liu Q, Lin CC, Dai H, et al
    mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer.
    Clin Cancer Res. 2015 Nov 6. pii: clincanres.1772.2015.
    PubMed     Text format     Abstract available


  103. MANNA S, Bostner J, Sun Y, Miller LD, et al
    ERRalpha is a marker of tamoxifen response and survival in triple-negative breast cancer.
    Clin Cancer Res. 2015 Nov 5. pii: clincanres.0857.2015.
    PubMed     Text format     Abstract available


  104. GINGRAS I, Desmedt C, Ignatiadis M, Sotiriou C, et al
    CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer-Where Did It Start and Where Are We Now?
    Clin Cancer Res. 2015;21:4743-6.
    PubMed     Text format     Abstract available


    October 2015
  105. LOI S, Dushyanthen S, Beavis PA, Salgado R, et al
    RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors.
    Clin Cancer Res. 2015 Oct 29. pii: clincanres.1125.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: